The Maternal Psychic Impact of Infection by SARS-CoV-2 during Pregnancy: Results from a Preliminary Prospective Study.

The Maternal Psychic Impact of Infection by SARS-CoV-2 during Pregnancy: Results from a Preliminary Prospective Study.

Publication date: Apr 30, 2024

Due to a higher risk of maternal complications during pregnancy, as well as pregnancy complications such as stillbirth, SARS-CoV-2 contamination during pregnancy is a putative stress factor that could increase the risk of perinatal maternal mental health issues. We included women older than 18 years, who delivered a living baby at the Geneva University Hospitals’ maternity wards after 29 weeks of amenorrhea (w. a.) and excluded women who did not read or speak fluent French. We compared women who declared having had COVID-19, confirmed by a positive PCR test for SARS-CoV-2, during pregnancy with women who did not, both at delivery and at one month postpartum. We collected clinical data by auto-questionnaires between time of childbirth and the third day postpartum regarding the occurrence of perinatal depression, peritraumatic dissociation, and peritraumatic distress during childbirth, measured, respectively, by the EPDS (depression is score > 11), PDI (peritraumatic distress is score > 15), and PDEQ (scales). At one month postpartum, we compared the proportion of women with a diagnosis of postpartum depression (PPD) and birth-related posttraumatic stress disorder (CB-PTSD), using PCL-5 for CB-PTSD and using diagnosis criteria according DSM-5 for both PPD and CB-PTSD, in the context of a semi-structured interview, conducted by a clinician psychologist. Off the 257 women included, who delivered at the University Hospitals of Geneva between 25 January 2021 and 10 March 2022, 41 (16. 1%) declared they had a positive PCR test for SARS-CoV-2 during their pregnancy. Regarding mental outcomes, except birth-related PTSD, all scores provided higher mean values in the group of women who declared having been infected by SARS-CoV-2, at delivery and at one month postpartum, without reaching any statistical significance: respectively, 7. 8 (+/-5. 2, 8:4-10. 5) versus 6. 5 (+/-4. 7, 6:3-9), p = 0. 139 ***, for continuous EPDS scores; 10 (25. 0) versus 45 (21. 1), p = 0. 586 *, for dichotomous EPDS scores (≥11); 118 (55. 7) versus 26 (63. 4), p = 0. 359 *, for continuous PDI scores; 18. 3 (+/-6. 8, 16:14-21) versus 21. 1 (+/-10. 7, 17:15-22), 0. 231 ***, for dichotomous PDI scores (≥15); 14. 7 (+/-5. 9, 13:10-16) versus 15. 7 (+/-7. 1, 14:10-18), p = 0. 636 ***, for continuous PDEQ scores; 64 (30. 0) versus 17 (41. 5), p = 0. 151 *, for dichotomous PDEQ scores (≥15); and 2 (8. 0) versus 5 (3. 6), p = 0. 289 *, for postpartum depression diagnosis, according DSM-5. We performed Chi-squared or Fisher’s exact tests, depending on applicability for the comparison of categorical variables and Mann-Whitney nonparametric tests for continuous variables; p < 0. 05 was considered as statistically significant. Surprisingly, we did not find more birth-related PTSD as noted by the PCL-5 score at one month postpartum in women who declared a positive PCR test for SARS-CoV-2:15 (10. 6) versus no case of birth related PTSD in women who were infected during pregnancy (p = 0. 131 *). Our study showed that mental outcomes were differently distributed between women who declared having been infected by SARS-CoV-2 compared to women who were not infected. However, our study was underpowered to explore all the factors associated with psychiatric issues during pregnancy, postpartum, depending on the exposure to SARS-CoV-2 infection during pregnancy. Future longitudinal studies on bigger samples and more diverse populations over a longer period are needed to explore the long-term psychic impact on women who had COVID-19 during pregnancy.

Open Access PDF

Concepts Keywords
Childbirth mental health issues
French pregnancy
Psychologist SARS-CoV-2
Underpowered

Semantics

Type Source Name
disease MESH Infection
disease MESH complications
disease MESH pregnancy complications
disease MESH stillbirth
disease MESH amenorrhea
disease MESH COVID-19
disease VO time
disease MESH dissociation
disease MESH postpartum depression
drug DRUGBANK p-Phenylenediamine
disease MESH posttraumatic stress disorder
pathway REACTOME SARS-CoV-2 Infection
drug DRUGBANK Coenzyme M
disease MESH morbidity
disease MESH acute respiratory distress syndrome
disease MESH pregnancy outcomes
disease MESH preeclampsia
disease MESH preterm birth
disease VO pregnant women
disease MESH high risk pregnancy
disease MESH anxiety disorders
disease VO population
disease VO vaccination
disease VO vaccinated
disease VO laboratory test
disease MESH marital status
disease IDO history
disease MESH hemorrhage
disease MESH postpartum hemorrhage
disease MESH Emergency

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *